09:06 AM EDT, 06/17/2025 (MT Newswires) -- Agenus ( AGEN ) said Tuesday that it has formed a research collaboration with Noetik to identify predictive biomarkers for its lead immuno-oncology combination, botensilimab and balstilimab.

Agenus ( AGEN ) said the collaboration will leverage Noetik's AI-powered OCTO virtual cell models, which are trained on extensive tumor data, to analyze clinical outcomes and gain deeper insights into tumor-immune system dynamics.